Kyverna Therapeutics Inc narrowed first quarter of 2025 net loss per share of $-1.03 compare to net loss per share of $-1.12 recorded in the same quarter a year ago a decrease compare to $-0.78 realized in previous quarter.
first quarter of 2025
Earnings Per Share
Revenues
$ -1.03
$
0 Mill
$+0.09
Unch.
Kyverna Therapeutics Inc 's Revenue
fell by
0 % in first quarter of 2025 (Mar 31 2025) year on year,
to $0 million and
declined by
sequentially.
Kyverna Therapeutics Inc in the first quarter of 2025 recorded net loss of $-44.635 million, an increase from net loss of $-26.693 million in I. Quarter a year ago.
Kyverna Therapeutics Inc
does not pay out common stock dividend.
In trailing twelve-month period Kyverna Therapeutics Inc payed $ -3.09 cash per share, on a free-cash flow basis
.
Book value fell by -25.57 % sequentially to $5.18 per share, -54.29% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 5.18 per share from $ 6.96.
Company
issued 4.93 million shares or 12.89 % in Mar 31 2025.
Kyverna Therapeutics Inc
does not pay out common stock dividend.
In trailing twelve-month period Kyverna Therapeutics Inc had negative $ -3.09 cash flow per share, on a free-cash flow basis
.
Book value fell by -25.57 % sequentially to $5.18 per share, -54.29% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 5.18 per share from $ 6.96.
Company
issued 4.93 million shares or 12.89 % in Mar 31 2025.
